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Immunotherapy may provide valid alternative therapy for patients with hormone-refractory 
metastatic prostate cancer. However, if the tumor environment exerts a suppressive action on 
antigen-specific tumor-infiltrating lymphocytes (TIL), immunotherapy will achieve little, if 
any, success. In this study, we analyzed the modulation of TIL responses by the tumor 
environment using collagen gel matrix–supported organ cultures of human prostate 
carcinomas. Our results indicate that human prostatic adenocarcinomas are infiltrated by 
terminally differentiated cytotoxic T lymphocytes that are, however, in an unresponsive status. 
We demonstrate the presence of high levels of nitrotyrosines in prostatic TIL, suggesting a 
local production of peroxynitrites. By inhibiting the activity of arginase and nitric oxide 
synthase, key enzymes of L-arginine metabolism that are highly expressed in malignant but 
not in normal prostates, reduced tyrosine nitration and restoration of TIL responsiveness to 
tumor were achieved. The metabolic control exerted by the tumor on TIL function was 
confirmed in a transgenic mouse prostate model, which exhibits similarities with human 
prostate cancer. These results identify a novel and dominant mechanism by which cancers 
induce immunosuppression in situ and suggest novel strategies for tumor immunotherapy.
 
Human tumors express antigens recognized by
T and B lymphocytes, a recent discovery that
has paved the way for the development of
novel immunotherapeutic strategies targeting
the immune effectors toward cancer-associated
antigens (1, 2). Unfortunately, the many attempts
to create a therapeutic cancer vaccine for human
tumors have been unsuccessful. Although vacci-
nation often succeeds in expanding circulating
T lymphocytes recognizing the autologous tu-
mor, only a limited number of clinically objec-
tive responses have been reported so far (3). T
lymphocytes activated by vaccination acquire
an antigen-experienced memory phenotype,
and they are virtually competent to attack neo-
plastic cells (4, 5). Thus, inefficacy of active
immunotherapy probably depends either on
the inability of sufficient lymphocyte numbers
to reach the site of cancer growth or on the
countermeasures orchestrated by tumor cells.
Tumor escape mechanisms are quite diversified;
they include loss of antigen, HLA molecules, or
key proteins of the antigen-processing machin-
ery; local production of immunosuppressive
molecules; recruitment and activation of sup-
pressive myeloid cells; and loss of costimulatory
molecules (6).
Among cancer patients undergoing active
immunotherapy, those showing mixed responses
are particularly intriguing (7). In clinical trials,
in fact, some tumor nodules regress or disappear,
whereas in the same patient others progress.
The reasons for this heterogeneous response
are not clear, but it was proposed that tumor
nodules might have different permissive states
toward the activity of anti-tumor lymphocytes
(7). The interactions between lymphocytes,
tumors, and tumor-infiltrating myeloid cells
can create a number of functional events that
range from full activation of specific immune
responses to the induction of tolerance in tu-
mor-specific T lymphocytes (8, 9). However,
in general, the tumor microenvironment does
not seem to be suitable for T lymphocyte
functions, and, indeed, a number of reports indi-
cate that tumor-infiltrating lymphocytes (TIL)
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are impaired in both signal transduction and effector systems
(10). These findings have been obtained mostly in nonvacci-
nated tumor-bearing hosts, but it is reasonable to assume that
the same constrains might apply to lymphocytes activated by
active immunotherapy once they reach the tumor site.
The control of amino acid metabolism is emerging as a
relevant immunoregulatory tool shared by different cell
types of the immune system, which can also underlie the im-
mune dysfunctions induced by tumors. The activation of the
tryptophan-degrading enzyme indoleamine 2,3-dioxygen-
ase in dendritic cells, originally associated with peripheral
tolerance and maternal tolerance toward the fetus, was re-
cently shown to be involved in tumor immune evasion. In
two different tumor models, systemic administration of a
specific indoleamine 2,3-dioxygenase inhibitor resulted in
partial reversion of the tumor-induced immunosuppression
(11, 12).
Tryptophan is not the only amino acid whose metabolism
is increased in a tumor-conditioned microenvironment, and
numerous reports suggest also a role for the activation of
L-arginine (L-Arg) metabolizing enzymes during tumor growth
and development. In tumor-infiltrating myeloid cells, L-Arg
is metabolized by arginase I (ARG1), arginase II (ARG2),
and by the inducible form of nitric oxide synthase (NOS2).
Cytoplasmic ARG1 and mitochondrial ARG2 hydrolize
L-Arg to urea and ornithine, the latter being converted to
polyamines by ornithine decarboxylase (13). NOS2 oxidizes
L-Arg to citrulline and nitric oxide (NO), a pleiotropic mol-
ecule important for ischemia, inflammation, angiogenesis,
immune response, and cell growth and differentiation (14).
Increased ARG activity has long been detected in pa-
tients with colon, breast, lung, and prostate cancer (15), and
it was proposed that this enzymatic activity sustained the
high demand of polyamines necessary to tumor growth (16).
However, ARG activity in macrophages infiltrating a mouse
tumor was recently shown to impair antigen-specific T cell
responses and the expression of the CD3 
 
 
 
 chain (17). In-
creased production of NO within various human cancers
may contribute to tumor development by favoring neoan-
giogenesis, tumor metastasis, and tumor-related immune
suppression (18). It is commonly believed that ARG and
NOS are competitively regulated by Th1 and Th2 cytokines
and complex intracellular biochemical pathways, including
negative feed-back loops and competition for the same sub-
strate (13). However, simultaneous activation of ARG and
NOS in myeloid cells licensed by the tumor can generate
powerful inhibitory signals, eventually leading to apoptotic
death of antigen-specific T lymphocytes (19, 20).
Figure 1. CD8  TIL infiltrate malignant prostate. (A) Single-cell 
suspensions obtained from 50 prostate samples were incubated with anti-
bodies to various T cell markers and analyzed by flow cytometry. A repre-
sentative experiment is reported. (B) Immunocytochemical detection of 
CD8  or CD4  TIL in PCa tissues (magnification,  400). 
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Evidence has been accumulating that ARG and NOS are
overexpressed in prostate cancers as compared with hyper-
plasic prostate (21–23), with the intriguing observation that
the tumor cells, rather than myeloid infiltrating cells, could
be the main source of the enzymes. We investigated whether
the alteration of L-Arg metabolism in tumor explants could
be responsible for the induction of TIL dysfunctions. When
small tumor samples are cultured in medium containing a
combination of ARG- and NOS-specific inhibitors, TIL re-
cover their functions, suggesting the presence of a predomi-
nant immunosuppressive mechanism based on the altered
L-Arg metabolism in prostate cancer.
 
RESULTS
Phenotypic analysis of prostate tumor-infiltrating 
lymphocytes
 
To characterize the phenotype of T lymphocytes infiltrating
human prostate carcinoma (PCa), prostate samples obtained
from untreated patients who underwent radical prostatec-
tomy for PCa were analyzed by FACS (BD Biosciences)
analysis and immunohistochemistry. Initial studies revealed
that TIL infiltrating PCa samples were mainly CD8
 
 
 
 T lym-
phocytes (Fig. 1, A and B); therefore the following experi-
ments were focused on CD8
 
 
 
 TIL.
CTL are one of the critical effector cells in antitumor
immunity (24). T cell differentiation from naive to effector
CTL can be analyzed through the expression of CCR7 and
CD45RA molecules (25). In PCa samples, CD8
 
 
 
 TIL were
either CCR7
 
 
 
CD45RA
 
 
 
CD62L
 
 
 
 (effector memory phe-
notype) or CCR7
 
 
 
CD45RA
 
 
 
CD62L
 
 
 
 (terminally differen-
tiated CTL) (Table I). Consistent with their phenotype of
terminally differentiated cytotoxic cells, CD8
 
 
 
 T lympho-
cytes infiltrating PCa expressed low levels of chemokine
receptors; an exception was CCR5, which is known to be
expressed in tissue-infiltrating lymphocytes. These cells con-
tained perforin granules, indicating that activated and armed
CTL are present within the tumor site (Table I). Interest-
ingly, CD8 TIL expressed high levels of activatory NK
receptors, such as p50.3, NKRP1A, NKG2D, and CD94
(Table I).
 
Tumor-infiltrating lymphocyte activation in prostate 
carcinoma organ cultures
 
Several studies have documented signaling defects in TIL,
and it has been proposed that the tumor itself, or host cells
present in the tumor environment, directly inhibits TIL acti-
vation (26, 27). To study the effect of prostate tumor envi-
ronment on T lymphocyte activation, TIL were stimulated in
situ, using collagen gel matrix–supported organ cultures of
PCa and tumor-free prostates (obtained from patients who
underwent radical prostatectomy for bladder cancer). The ad-
vantage of using PCa organ cultures is that the tumor mi-
croenvironment remains intact during the experiment. Thus,
all the factors that may affect TIL function, such as cell–cell
interactions, cell–matrix interactions, and interstitial fluid
within this three-dimensional milieu, are preserved (28). We
found that, although CD8
 
 
 
 T lymphocytes in tumor-free
samples responded to the stimuli provided (i.e., PHA or
PMA plus ionomycin), as shown by up-regulation of activa-
tion markers, CD8
 
 
 
 TIL from PCa samples were totally un-
responsive to stimulation (Fig. 2). TIL responsiveness was not
 
Table I.
 
Phenotypic analysis of CD8
 
 
 
 T cells infiltrating 
human PCa
 
Antigen Expression
No. of patients
analyzed
 
T cell markers
CD5
 
   
 
a
 
4
CD7
 
   
 
4
CD11a
 
   
 
4
CD25
 
 
 
50
CD26
 
 
 
4
CD27
 
 
 
4
CD28
 
 
 
25
CD31
 
 
 
4
CD45RA
 
 
 
12
CD62L
 
   
 
12
CD69
 
 
 
50
CD137
 
 
 
50
NK receptors
p50.3
 
  
 
4
p58.1
 
 
 
4
p58.2
 
 
 
4
NKAT
 
 
 
4
NKB1
 
 
 
4
NKG2A
 
  
 
4
NKG2C
 
 
 
4
NKG2D
 
  
 
4
NKRP1A
 
   
 
4
NKp30
 
 
 
4
NKp44
 
 
 
4
NKp46
 
 
 
4
CD94
 
  
 
4
Chemokine receptors
CCR4
 
 
 
4
CCR5
 
   
 
4
CCR6
 
 
 
4
CCR7
 
 
 
12
CXCR1
 
 
 
4
CXCR2
 
 
 
4
CXCR3
 
  
 
4
CXCR4
 
  
 
4
Functional marker
Perforin
 
   
 
12
 
a
 
Fraction of cells expressing a given marker: 
 
 
 
, 0–10%; 
 
   
 
, 10–20%; 
 
 
 
, 20–60%; 
 
  
 
, 60–80%; 
 
   
 
, 80%. 
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restored by the addition of IL-2 to the culture medium (un-
published data). In contrast, peripheral blood CD8
 
 
 
 T cells
obtained from PCa patients or healthy donors were similar in
responsiveness to the provided stimuli (Fig. 3), thus excluding
the possibility that the PCa patients analyzed were immuno-
depressed. Taken together, these data suggest that the PCa
environment is immunosuppressive for CD8
 
 
 
 T cells.
 
Arginine and nitric oxide synthase mediate prostate 
carcinoma immunosuppression
 
It has been proposed that alterations of L-Arg metabolism in
the tumor environment could impair T cell functions (20).
NOS2 is expressed in the prostate of various species, includ-
ing humans. Up-regulated NOS2 expression was demon-
strated in PCa and was shown to be predictive of poor sur-
vival (23). Together with the enzyme diamine oxidase,
ARG controls polyamine metabolism in prostatic tissue. Ex-
perimental evidence indicates that ARG activity is elevated
in PCa tissues as compared with benign prostatic hyperplasia,
suggesting that this enzyme might play a role in the PCa
progression (21). In the light of these data, tumor-free and
PCa samples were subjected to immunohistochemical analy-
ses for NOS2 and ARG2. We found that the expression of
both enzymes was highly up-regulated in the tumor tissues
(Fig. 4). This finding prompted us to investigate whether the
two enzymes might be involved in the selective T cell unre-
sponsiveness that we observed in PCa. Tumor tissue cultures
were incubated for 4 d in the presence or in the absence of
specific inhibitors of NOS (l-NMMA) and ARG (NOHA);
then CD8
 
 
 
 T cell phenotype was analyzed. In 64% of the
patients analyzed (
 
n
 
 
 
 
 
 33), CD8
 
 
 
 T cells infiltrating tumor
tissue cultures treated with l-NMMA and NOHA spontane-
ously up-regulated the expression of the early-activation
markers CD25, CD69, and CD137 (Fig. 5 A). Up-regula-
tion of activation markers was not the result of a direct effect
of l-NMMA and NOHA on TIL, because the expression of
the same molecules in CD8
 
 
 
 T cells infiltrating tumor-free
prostates treated with the same protocol did not change (un-
published data). Moreover, if the treatment with NOS and
ARG inhibitors was prolonged for 7 d, the number of viable
CD8
 
 
 
 T cells in PCa organ cultures was significantly higher
than in untreated tumors (0.70 
 
 
 
 0.29% vs. 0.22 
 
 
 
 0.08% of
the gated, live cells recovered after tumor dissociation), indi-
cating that treatment with NOS and ARG inhibitors pre-
vents T cell death in the tumor samples (Fig. 5 B). It is im-
portant to note that, in every experiment, each prostate
sample was divided in two parts; one part was cultured with
inhibitors and the other in normal medium. Only samples
from the same patient were compared. Thus, the different
phenotypes of TIL in treated or untreated samples can as-
cribed only to the inhibitor’s effects, not to individual vari-
ability among the samples. When the two enzymes were not
used in combination (i.e., when only NOS or only ARG ac-
tivity was inhibited), TIL phenotype remained unmodified,
indicating that both pathways must be blocked to reverse T
cell inhibition (unpublished data).
Figure 2. TIL in PCa organ cultures are unresponsive. PCa (n   20) 
and tumor-free prostate (n   10) samples were cultured for 48 h in the 
presence or in the absence of PHA (1  g/ml) or PMA (50 ng/ml) plus iono-
mycin (0.5  g/ml). After enzymatic digestion, the single-cell suspensions 
obtained from prostate were incubated with antibodies to CD8 plus anti-
bodies to CD25, CD69, and CD137. Flow cytometric analyses were gated 
on CD8  lymphocytes. Similar results were obtained when prostate 
samples were cultured in the presence of IL-2 (100 U/ml). Results are 
expressed as fold of induction above the mean fluorescence intensity of 
unstimulated samples, which was taken as 1. *, P   0.05 compared with 
tumor-free prostate samples. Mean fluorescence intensity values from a 
representative experiment are shown in the accompanying table.
Figure 3. PBL of PCa patients have normal responses to stimuli. 
PBL from healthy donors (n   10) or from the same PCa patients whose 
prostate samples were analyzed as described in Fig. 2 (n   20) were cultured 
for 48 h in the presence or in the absence of PHA (1  g/ml) or PMA (50 ng/ml) 
plus ionomycin (0.5  g/ml). Cells were incubated with antibodies to CD8 
plus antibodies to CD25, CD69, and CD137. Flow cytometric analyses were 
gated on CD8  lymphocytes. Similar results were obtained when all CD3  
T cells were analyzed. Results are expressed as fold of induction above the 
mean fluorescence intensity of unstimulated samples, which was taken as 1. 
JEM VOL. 201, April 18, 2005
 
1261
 
ARTICLE
 
Arginine and nitric oxide synthase activities induce tyrosine 
nitration in tumor-infiltrating lymphocytes
 
We then tried to investigate the downstream events of ARG-
and NOS-mediated immunosuppression in PCa. It has been
proposed that under conditions of low L-Arg concentrations
caused by enhanced ARG activity, NOS generates O
 
2
 
 
 
 that
reacts with NO to generate peroxynitrites (ONOO
 
 
 
) that, in
turn, cause protein tyrosine nitration and inhibit activation-
induced protein tyrosine phosphorylation (29, 30). To test
this hypothesis, we analyzed PCa samples, precultured in the
presence or in the absence of l-NMMA and NOHA, for ni-
trotyrosine expression. PCa tissues contained several cells
highly positive for nitrotyrosine staining (Fig. 6 A). Interest-
ingly, in PCa samples cultured in the presence of ARG and
NOS inhibitors, the number of nitrotyrosine-expressing cells
was considerably decreased (Fig. 6 A), indicating that protein
nitration is not permanent and that possible denitration
mechanisms might exist within the tissue (31, 32).
To associate T cell dysfunctions with nitrotyrosine gen-
eration, it was essential to show the presence of nitroty-
rosines in CD8
 
 
 
 TIL. Therefore, PCa samples were analyzed
for nitrotyrosine expression by flow cytometric analyses. Ni-
trotyrosines were present in PCa TIL, and treatment with
ARG and NOS inhibitors reduced their expression (Fig. 6
B), indicating that in PCa the enhanced activity of the en-
zymes ARG and NOS generates peroxynitrite responsible
for tyrosine nitration and in situ immunosuppression of TIL.
 
Arginine and nitric oxide synthase inhibitors restore local 
tumor recognition by tumor-infiltrating lymphocytes
 
Frey and collaborators have shown that murine CD8
 
 
 
 TIL do
contain cytolytic granules, but these granules are diffused in
the cytoplasm and do not polarize in response to T cell stimu-
lation (33). Moreover, they showed that recovery of lytic
function, after isolation and culture of TIL, correlated with
the capacity of TIL to mobilize and polarize cytotoxic gran-
ules. We decided to analyze the subcellular localization of cy-
tolytic granules in CTL infiltrating PCa samples untreated or
incubated for 4 d with ARG and NOS inhibitors. A cytotoxic
granule–associated protein, TIA-1, was used as a specific
granule marker (34, 35). Immunohistochemical and immuno-
Figure 4. Higher expression of NOS2 and ARG2 in PCa tissues than 
in tumor-free prostatic tissues. Immunohistochemical detection of 
NOS2 and ARG2 in control (n   2) and malignant prostatic tissues (n   4).
Figure 5. ARG2 and NOS2 mediate PCa immunosuppression. PCa 
tissues were cultured 4 d in the presence or in the absence of NOS (l-NMMA; 
0.5 mM) plus ARG (NOHA, 0.5 mM) inhibitors. (A) After 4 d of culture, the 
PCa tissues (n   33) were digested, and the cell suspensions obtained 
were incubated with antibodies to CD8 plus antibodies to CD25, CD69, and 
CD137. Flow cytometric analyses were gated on CD8  lymphocytes. Results 
are expressed as fold of induction above the mean fluorescence intensity 
of untreated samples of the same patient, which was taken as 1 . *, P   0.05 
compared with untreated samples. Mean fluorescence intensity values 
from a representative experiment are shown in the accompanying table. 
(B) After 7 d of culture, the PCa tissues (n   21) were digested, and the 
cell suspensions obtained were incubated with antibodies to CD8 plus 
propidium iodide (PI). Data are presented as viability index over untreated 
tumor cultures of the same patients (number of CD8  PI  cells in treated 
samples/number of CD8  PI  cells in untreated samples).HUMAN PROSTATE CANCER-MEDIATED IMMUNOSUPPRESSION | Bronte et al. 1262
fluorescence analysis revealed that lytic granules were evenly
distributed in the cytoplasm of CD8  T cells present in PCa
samples, suggesting that CTL do not engage productive con-
tacts or are unable to organize a mature immunological syn-
apse inside the tumor (Fig. 7, A and B). However, when PCa
samples were precultured with l-NMMA and NOHA, the
subcellular distribution of CTL lytic granules seemed to be
polarized in a restricted region of the cytoplasm, suggesting
that functional immunological synapses between CTL and
target cells were organized (Fig. 7, A and B). TIA-1  cells
present in PCa samples, treated or untreated with ARG and
NOS inhibitors, from three different patients were counted.
We found that tumor tissues preincubated or not with
l-NMMA and NOHA had comparable numbers of TIA-1 
cells. However, polarized granules were expressed by less than
10% of the positive cells in untreated tumors, whereas more
than 90% of TIA-1  cells displayed a polarized phenotype in
tumors incubated with ARG and NOS inhibitors.
Polarization and release of CTL lytic granules result in
killing of the target cell. Thus, we analyzed PCa tissue cul-
tures, preincubated or not with ARG and NOS inhibitors, for
the presence of apoptotic cells. Apoptosis was almost unde-
tectable in untreated tumor tissue cultures (less than two apop-
totic cells/sample), but more than 20 isolated apoptotic cells
per sample were present in tissues incubated with l-NMMA
and NOHA, suggesting that selective killing had occurred
(Fig. 7 C). The possibility that the inhibitors used directly in-
duce cell death can be ruled out because (a) few and isolated
apoptotic cells were present in the tissues, and (b) the number
of apoptotic cells correlated with the number of TIA-1  cells.
To clarify the identity of the apoptotic cells and the role
of cytotoxic T cells in mediating the observed apoptosis in
tumor samples treated with NOS and ARG inhibitors, we
performed a double staining for TIA-1 and apoptosis (Fig. 7
D). The results indicate that apoptotic cells are not lympho-
cytes but are surrounded by TIA-1  cells, thus strengthening
evidence for the role of CTL in mediating apoptosis inside
the tumor.
Taken together, these data indicate that CTL infiltrating
human prostate cancer are potentially able to kill tumor cells
and that their in situ lytic function can be restored by inhib-
iting ARG2 and NOS2.
Arginine and nitric oxide synthase inhibitors restore 
antitumor activity in prostate carcinoma cultures of 
transgenic adenocarcinoma mouse prostate mice
We were not able to recover enough human T lymphocytes
from PCa organ cultures to perform functional studies. We
therefore decided to use a mouse model very close to the
human pathology: the transgenic adenocarcinoma mouse
prostate (TRAMP) mouse. These mice are transgenic for the
SV40 large-antigen (Tag) oncogene under the control of the
rat probasin regulatory element and express Tag at puberty.
In the following weeks, TRAMP mice progressively de-
velop spontaneous prostatic hyperplasia, adenocarcinoma,
and lymph node and lung metastases, closely mimicking pro-
gression of human PCa (36). Another interesting analogy
with human tumors directly concerns the scope of our stud-
ies: the invading, but not the normal, epithelium overex-
presses both ARG and NOS (unpublished data). At 22–24
wk of age, prostatic intraepithelial neoplasia and well-differ-
entiated carcinoma comprised the majority of the pathology
in TRAMP mice, but the tumor appearance was variable,
ranging from microscopic tumors evidenced only histologi-
cally to macroscopically visible nodules in the pelvis where
the individual mouse prostate lobes were indistinguishable
(36). The first type of tumors was infiltrated by a sizeable
number of CD8  T lymphocytes (12.66   1.09% of the
gated, live cells recovered after tumor dissociation) with the
phenotype of memory/effector cells, as assessed by the ex-
pression of CD62L, CD44, and CD25 (Fig. 8 A). In large
tumors, the percentage of CD8  T lymphocytes declined
dramatically (0.15   0.01% of gated cells), and these lym-
phocytes had almost completely lost the expression of
CD25, the   chain of the IL-2 receptor (Fig. 8 A). Large tu-
mors were then enzymatically dissociated, pooled, and cul-
tured in the presence of high doses of IL-2 to expand TIL.
Equivalent numbers of the same cellular preparation were
cultured in the presence of the ARG and NOS inhibitors
used in previous experiments, low doses of IL-2, or a combi-
Figure 6. ARG and NOS inhibitors reduce the level of nitrotyrosines 
in PCa tissues and in TIL. PCa samples (n   6) were cultured 4 d in the 
presence or in the absence of NOS (l-NMMA; 0.5 mM) plus ARG (NOHA; 0.5 
mM) inhibitors. (A) Immunohistochemical detection of nitrotyrosines in 
treated or untreated samples. Arrows indicate highly positive cells present 
only in untreated PCa tissues. (B) Flow cytometric analysis for nitrotyrosine 
expression in CD8  cells infiltrating treated or untreated PCa samples.JEM VOL. 201, April 18, 2005 1263
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nation of inhibitors and low IL-2 concentration. After 3 wk,
TIL were recovered and tested for their ability to recognize
different targets by releasing IFN-  (Fig. 8 B). No TIL were
recovered in cultures incubated only with the inhibitors (un-
published data), an expected result in the absence of IL-2
driving the expansion of the activated T lymphocytes. High-
dose IL-2 allowed the highest cell recovery (3.48   106;
464-fold expansion), but TIL had a very high background
IFN-  release, which did not allow discriminating any tu-
mor-specific recognition. Low-dose IL-2 combined with
the ARG and NOS inhibitors allowed recovery of an inter-
mediate number of TIL (2.56   106; 341-fold expansion)
that recognized the autologous tumor, the syngeneic pros-
tate cancer cell line TRAMP C1, and the SV40-infected fi-
broblast but not normal splenocytes or tumors of different
histology (MBL-2 and B16 tumors), suggesting the expan-
sion of tumor-specific and possibly SV40-restricted effectors.
Low-dose IL-2 alone supported a lower expansion (138-
fold; 1.24   106 total cells) of TIL that only partially recog-
nized the autologous tumor and SV40  fibroblasts but not
TRAMP C1 cells (Fig. 8 B). These data confirm the rele-
vance of ARG and NOS in restraining tumor-specific lym-
phocytes in PCa and suggest that the lymphocyte repertoire
generated by altering the local L-Arg metabolism in the
presence of IL-2 might be different from that obtained by
the simple IL-2–driven activation.
DISCUSSION
A long-term clinical follow-up of more than 300 patients
with prostate adenocarcinomas (PCa) showed a significant
correlation between the TIL density and prognosis (37). Ab-
sent or weak TIL were found to be signs of increased tumor
progression risk and poor prognosis. However, a major limit
of similar epidemiological studies (38) is that lymphocytic in-
Figure 7. ARG and NOS inhibitors restore CTL lytic function. 
(A) Immunohistochemical detection of TIA-1 in PCa samples (n   10) 
cultured 4 d in the presence or in the absence of NOS (l-NMMA; 0.5 mM) 
plus ARG (NOHA; 0.5 mM) inhibitors. The pictures show that in untreated 
tumor samples cytotoxic granules are evenly distributed in the cytoplasm 
of CTL (black arrow). In contrast, in tumor samples cultured with inhibitors, 
CTL cytotoxic granules appear polarized in a confined region of the cell 
(green arrow: magnification,  1,000). In each experimental condition, 500 
TIA-1  cells were analyzed. In untreated samples, we counted 23 TIA-1  
cells showing a polarized phenotype (4.6%), whereas in samples cultured 
in the presence of ARG and NOS inhibitors we counted 461 polarized cells 
(92.2%). (B) Similar results were obtained by immunofluorescence analysis 
of TIA-1  cells. Bar, 10  m. (C) Immunohistochemical detection of apop-
tosis by TUNEL assay in PCa samples (n   10) cultured 4 d in the presence 
or in the absence of NOS (l-NMMA; 0.5 mM) plus ARG (NOHA; 0.5 mM) 
inhibitors. Apoptotic cells are indicated (black arrow). In untreated tissues, 
apoptotic cells were always less than two/sample, whereas in inhibitor-
treated tissues we counted  20 apoptotic cells per sample (magnification, 
 600). (D) Immunofluorescence analysis of TIA-1  cells and apoptosis. PCa 
samples (n   10) cultured 4 d in the presence of NOS (l-NMMA; 0.5 mM) 
plus ARG (NOHA; 0.5 mM) inhibitors stained for TIA-1 (red) and subse-
quently for DNA fragmentation by TUNEL assay (green). Samples were 
analyzed by confocal microscopy. Bar, 10  m. Cell margins were drawn to 
facilitate the readers.HUMAN PROSTATE CANCER-MEDIATED IMMUNOSUPPRESSION | Bronte et al. 1264
filtration is present in benign hyperplasia as well, leaving un-
answered the question whether TIL represent a lymphocytic
nonspecific inflammation or a true, evolving tumor-specific
immune response. In many melanomas, it has been conclu-
sively shown that TIL are directed against either melanocyte
differentiation antigens or mutated proteins, and they can be
expanded ex vivo to exert antitumor activity after adoptive
transfer to the patient (39). In the case of prostate cancer,
there are few reports. However, peptide-pulsed autologous
DC were able to stimulate prostate TIL and induce recogni-
tion of an HLA-A2-restricted epitope of the antigen parathy-
roid hormone-related protein, suggesting that TIL separated
from their surrounding environment possess full antigen re-
sponsiveness (40). In some cases TIL from PCa, isolated and
kept in culture in the presence of IL-2 for at least 14 d, were
capable of killing tumor cells via perforin-dependent and
-independent pathways only when tumor cells were previ-
ously treated with chemotherapeutic drugs (41).
Many of these studies, however, suffer from the limita-
tion that T lymphocytes are activated after repeated in vitro
stimulations in a disrupted tumor environment. Within the
tumor site, tumor-specific lymphocytes are sensitive to any
changes in the microenvironment, and these changes can
condition their function and activation state. Most solid tu-
mors are characterized by lymphocyte infiltration, but TIL
frequently are unable to kill autologous tumor cells, indicat-
ing that they are in an anergic/tolerant state (26, 27, 42, 43).
The data presented here provide new insight into the biol-
ogy of T lymphocytes infiltrating human PCa. TIL within
PCa are mainly CD8  T lymphocytes with an antigen-expe-
rienced, terminally differentiated phenotype. However, they
remain in a dormant state that is not altered by cytokines af-
Figure 8. ARG and NOS inhibitors are essential to restore full tumor 
recognition by TIL. (A) Single-cell suspensions obtained from three or 
four pooled prostate samples from TRAMP mice with small (left) and large 
(right) tumors, were incubated with antibodies to various T cell markers 
and analyzed by flow cytometry. A representative experiment is reported. 
(B) PCa large nodules from three TRAMP mice were enzymatically digested 
and, after removal of dead cells, were cultured in complete medium alone 
(to obtain the autologous tumor), in the presence of 100 IU/ml IL-2 (high 
IL-2), 10 IU/ml IL-2 (low IL-2), 0.5 mM l-NMMA plus 0.5 mM NOHA (inhib-
itors), or a combination of inhibitors and low-dose IL-2 (low IL-2 plus 
inhibitors). TIL recovered after 3 wk were used as effectors against a panel 
of target cells to evaluate the release of IFN-  after 24-h coincubation. 
The percentage of CD8  T lymphocytes in different preparations was 
greater than 80%. Data are from triplicate wells   SE. The experiment was 
repeated twice and, although the cell recovery differed, results of the 
IFN-  release assay were comparable. *, P   0.05 compared with TIL 
cultured in low IL-2 alone.JEM VOL. 201, April 18, 2005 1265
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fecting T lymphocyte proliferation such as IL-2. Unlike nor-
mally responsive lymphocytes in tumor-free prostates and
peripheral blood, TIL are not activated locally by powerful
signals acting either on TCR or downstream signaling path-
ways. The steady-state regulation of the dormant state is de-
pendent on the enhanced intratumoral metabolism of the
amino acid L-Arg, because the simple addition of ARG- and
NOS-specific inhibitors was sufficient to rouse these CTL,
activate them, and start a number of events leading to cy-
tolytic granule polarization and killing of cognate targets.
These data were confirmed and extended in TRAMP mice,
allowing us to evaluate the tumor-specific reactivity of TIL
rescued from the dormant state by the ARG and NOS in-
hibitor and expanded by low doses of IL-2.
Our findings suggest that the L-Arg–metabolizing en-
zymes are up-regulated in prostate cancer cells rather than in
tumor-infiltrating myeloid cells such as macrophages, al-
though we cannot rule out the contribution of these latter
cells. In line with our results, it is known that several tumor
cell lines express high levels of ARG and that inhibition of
arginase activity often abolishes in vitro cell growth (15). Our
data, together with the recent literature, suggest that intratu-
moral arginase induction might be beneficial for the tumor
through different pathways, i.e., supporting tumor growth
and development by providing polyamines and suppressing
antitumor immune response by negatively affecting TIL.
NOS activity has been detected in many human tumors,
including prostate cancer, although its function is unclear
(18, 23). NO stimulates angiogenesis, thus enhancing tumor
growth and invasiveness (44). Moreover, NO induced an
enhanced expression of the DNA-dependent protein-kinase
catalytic subunit, DNA-PKcs, that should protect tumor
cells from the damaging activity of NO and other DNA-
damaging agents, such as X-ray radiation, Adriamycin, bleo-
mycin, and cisplatin (45).
Depletion of cytosolic L-Arg content by ARG might
trigger the generation of superoxide (O2
-) from the NOS2
reductase domain (46, 47). The reductase domain of NOS2
generates O2
  that reacts immediately with NO generated
by the oxygenase domain. The chemical byproducts of this
reaction are ONOO , highly reactive oxidizing agents that
nitrate protein-associate tyrosines and damage different bio-
logical targets (48). Cell membranes offer no significant bar-
rier to diffusion of peroxynitrites from different compart-
ments, within or between cells, at a rate that is faster than the
known decomposition pathways of these moieties (49). This
lack of a barrier indicates that, whenever O2
  and NO are
generated from the same or different cells in a microenviron-
ment, they will immediately associate, and the resulting
ONOO  will diffuse freely through cell membranes.
A number of lines of evidence indicate that peroxyni-
trites are quite toxic for lymphocytes: they can prime T lym-
phocytes to undergo apoptotic cell death through different
pathways involving inhibition of protein tyrosine phosphor-
ylation via nitration of tyrosine residues (29, 30) or by nitra-
tion of the protein voltage-dependent anion channel, a com-
ponent of mitochondrial permeability transition pore (50).
Nitrotyrosine, a marker of peroxynitrite activity in tissues, is
found in thymic extracts and thymic sections colocalized
with apoptotic cells, suggesting that peroxynitrites are also
involved in thymic apoptosis in vivo (29). Staining for nitro-
tyrosine in PCa tissue sections gave a diffuse pattern with
some hot spots in the TIL. Whether T lymphocytes are
more prone to the effect of ONOO  and their decomposi-
tion by-products or instead activate additional intracellular
pathways for nitrotyrosine generation is not known. Indeed,
recent data suggest that protein nitration can be considered a
cellular signaling mechanism, because it is specific and re-
versible (51–53). Although the biochemical pathway respon-
sible for tyrosine denitration is not known, our results indi-
cate that CTL posses a mechanism capable of eliminating
nitrotyrosines and rescuing T cell functions.
As in previous mouse studies, inhibition of both ARG
and NOS was crucial to rescue T cell functions. We are cur-
rently investigating the mechanism for such synergy. How-
ever, in addition to having a synergistic activity in peroxyni-
trite generation, ARG and NOS can exert independent
inhibitory activities on T lymphocytes, as shown in different
tumor models. ARG depletes L-Arg in local microenviron-
ments, leading to loss of the CD3   chain in T lymphocytes
and their functional paralysis after antigen recognition (17),
whereas NO blocks the signaling through the IL-2 receptors
of T lymphocytes by impeding phosphorylation of the intra-
cellular signaling proteins STAT5, Akt, and Erk (20).
A number of studies have proposed that cancers induce
immunosuppression by inhibiting CD3   chain expression in
T lymphocytes (for review see reference 54). We analyzed
the expression of CD3   chain in both PBL and TIL from
PCa patients, but we were unable to demonstrate its down-
regulation (unpublished data). Moreover, PBL from PCa pa-
tients responded normally to all the stimuli we provided, in-
dicating that no evident signaling defects were present. In
contrast, TIL from PCa patients were unresponsive even
when stimulated with PMA plus ionomycin, stimuli that by-
pass TCR signaling. Altogether, these data indicate that in
PCa the ARG2 activity does not induce immunosuppression
through CD3   down-regulation.
Although it seems that the number of TIL in the tumor
might correlate with prognosis (37, 38, 55), it is suggested that
TIL are functionally deficient and that this deficiency is tran-
sient and attributable to the tumor environment because, on
purification from tumor cells, tumor-specific killing can be de-
tected (33, 56, 57). CTL kill their target cell by polarized secre-
tion of their lytic granules at the immunological synapse (58,
59). Polarization and secretion of lytic granules are triggered by
recognition of MHC class I–peptide complexes on the target
cell through the T cell receptor (60). Therefore, our results
showing that inhibition of ARG and NOS activities in the tu-
mor results in spontaneous polarization of cytotoxic granules in
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terminally differentiated cytotoxic T cells that are in contact
with the target cell but are unable to kill because they are nar-
cotized by the tumor environment. However, even inside the
tumor, CTL activity can be restored pharmaceutically.
Based on our findings, drugs controlling ARG and NOS
might be useful in aiding immunotherapeutic approaches for
the treatment of cancer by creating a favorable tumor environ-
ment for the T lymphocyte effector program. Molecules are
being developed to create novel isozyme-specific inhibitors for
both NO synthases and arginases (61, 62), but more must be
done to enhance selectivity. ARG1 is found at highest concen-
trations in the mammalian liver where it carries out the final
cytosolic step of the urea cycle, a process that allows the dis-
posal of nitrogenous waste. Arginase inhibitors might thus
cause hyperammonemia and interfere with hepatic urea cycle.
Moreover, some activities of inhibitors are not predictable. For
example, the effect of N -nitro-l-arginine methyl ester, con-
sidered a selective NOS2 antagonist, requires reconsideration,
because it can also inhibit arginase both in vivo and in vitro
(63). Thus, the identification of the specific biochemical path-
ways responsible for immunosuppression, such as the protein
nitration described here, may allow the development of more
specific and less toxic immunoprotective molecules.
MATERIALS AND METHODS
Prostate specimens. This study was examined and approved by the Eth-
ics Committee of the local Health and Social Services (Azienda Ospedaliera,
Padova) in accordance with the ethical standards laid down in the 1964
Declaration of Helsinki.
Prostate cancer specimens from 79 patients (aged 52–76 yr) who had
undergone radical prostatectomy were obtained from the Department of
Urology, Hospital of the University of Padova. None of these patients had
received preoperative antitumor therapy. Benign prostates were obtained
from patients who had undergone radical prostatectomy for bladder cancer
(n   18). Immediately after the surgery, the prostate specimens were di-
vided and sent to the laboratory. Diagnosis was performed by a team of sur-
gical pathologists at the Hospital.
Isolation of T cells from peripheral blood and tumor. After remov-
ing necrotic areas and fat, 100–120-mm3 tumor specimens were washed in
PBS and minced into small pieces using bistouries. From this tumor material
104–105 TIL were obtained after 2-h digestion at 37 C using a mixture of
enzymes dissolved in RPMI 1640 medium (collagenase type IV, 1 mg/ml;
deoxyribonuclease, 30 U/ml; and hyaluronidase, 0.1 mg/ml; all from
Sigma-Aldrich). The resulting cell suspension was passed over a 30- m fil-
ter, washed in RPMI 1640 medium (GIBCO BRL), and prepared for im-
munocytometric analysis.
PBL from both healthy donors and patients were isolated from heparin-
ized blood by centrifugation on Ficoll gradient (Ficoll-Paque PLUS, Amer-
sham Biosciences). PBL were cultured (37 C, 5% CO2) in RPMI 1640 me-
dium supplemented with 10% FCS, 1% L-glutamine, and 1% penicillin/
streptomycin (all obtained from GIBCO BRL).
Prostate organ cultures. Immediately after surgery, 100–120-mm3 tu-
mor sections were brought to the laboratory. After removal of necrotic tis-
sues, prostate samples were cut in 2–3-mm3 pieces and placed on presoaked
collagen sponges (Johnson & Johnson) in complete RPMI 1640 medium
(RPMI 1640 with 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin,
1% nonessential amino acids, and 1% sodium pyruvate).
Cultures were placed in six-well plates, and 3 ml of medium was added
to each well to reach the upper part of the gel without submerging the
prostate samples. Cultures were incubated at 37 C, in a humidified atmo-
sphere of 95% air and 5% CO2.
In some experiments, phytohemagglutinin (1  g/ml; Sigma-Aldrich)
or phorbol myristate-acetate (50 ng/ml; Sigma-Aldrich) plus ionomycin
(0.5  g/ml; Sigma-Aldrich), with or without IL-2 (100 IU/ml; Chiron
Corp.), were added to the cultures. In other experiments, N-hydroxy-
l-arginine (0.5 mM; Cayman Chemical) and l-NMMA (0.5 mM; Cayman
Chemical) were added to the cultures.
Monoclonal antibodies and flow cytometry. The following panel of
commercially available directly conjugated mAbs was included in this study:
CD3, CD4, CD5, CD7, CD8, CD25, CD26, CD28, CD45RA,
CD45RO, CD56, CD62L, CCR4, CXCR4, CCR5, CCR6, NKAT,
NKB1, CD94, and antiperforin obtained from BD Biosciences; CD27 and
CD31 obtained from Caltag Laboratories; CXCR3 and CCR7 obtained
from R&D Systems; CD137 obtained from Ancell Corporation; NKp30,
NKp44, NKp46, p50.3, p58.1, p58.2, NKG2A, and CD161 obtained from
Immunotech; and mAb antinitrotyrosine obtained from Upstate Biotech-
nology. Intracellular markers (nitrotyrosine and perforin) were stained in
cells previously fixed and permeabilized with a Fix and Perm kit (Caltag
Laboratories) according to the manufacturer’s manual.
The expression of these antigens on TIL and PBL was assessed by flow
cytometry analysis (FACS-Calibur or FACS Canto; Becton Dickinson) us-
ing direct or indirect immunofluorescence assay combining up to six fluo-
rescences (FITC, PE, PE-Cy5, PE-Cy7, APC, and APC-Cy7). A gate on
CD8  cells was defined for each sample, and dead cells were gated out
based on their scatter properties and propidium iodide (25  g/ml; Sigma-
Aldrich) incorporation. For the staining of mouse TIL, the following anti-
bodies were used: rat anti–mouse CD8-Tri-color (0.1  g/106 cells; clone
CTCD8 , Caltag Laboratories); hamster anti–mouse CD3-FITC (1  g/106
cells; clone 145-2C11, Caltag Laboratories); FITC- or BIOTIN-labeled rat
anti–mouse CD62L, CD25, CD44 (BD Biosciences); and isotype-matched
controls (Caltag Laboratories). Data were processed using CELLQUEST
(Becton Dickinson) or FlowJo (Tree Star, Inc.).
Cell lines. B16, a melanoma cell line of C57BL/6 (H-2b) provided by N.
Restifo (Surgery Branch, National Institutes of Health), MBL2 (H-2b) a
Moloney virus-induced lymphoma, and C57SV fibroblasts (H-2b SV40-
transformed fibroblasts) provided by P.L. Lollini (Istituto di Cancerologia,
Bologna, Italy) were maintained in DMEM (Invitrogen) supplemented with
2 mM L-glutamine, 10 mM Hepes, 20  M 2-ME, 150 U/ml streptomycin,
200 U/ml penicillin, and 10% heat-inactivated FCS (Invitrogen). TRAMP-
C1, a cell line established from a primary tumor in the prostate of a PB-Tag
C57BL/6 (TRAMP) mouse, was provided by N.M. Greenberg (Baylor
College of Medicine, Houston, Texas). This cell line was maintained in
DMEM high glucose (Invitrogen) supplemented with 2 mM L-glutamine,
10 mM Hepes, 20  M 2-ME, 150 U/ml streptomycin, 200 U/ml penicil-
lin, 10 8 DHT (Sigma-Aldrich), 5  g/ml insulin (Sigma-Aldrich), and 5%
heat-inactivated FCS (Invitrogen).
Mice. 6–8-wk-old male C57BL/6 (H-2b) mice were purchased from
Charles River Laboratories. TRAMP mice, a gift from N.M. Greenberg,
were bred in our facility and used for experiment at age 22–24 wk. Proce-
dures involving animals and their care were in conformity with institutional
guidelines that comply with national and international laws and policies.
Mouse tumor-infiltrating leukocyte generation. Tumor prostates
were surgically removed from TRAMP mice. Enzyme medium (DNase, 300
U/ml,   hyaluronidase, 0.1%,   collagenase, 1%) was used for the dissociation
of tumor biopsies to single-cell suspensions. After Ficoll centrifugation, these
suspensions were cultured for TIL outgrowth. In brief, 0.5   106 cells were
cultured in 24-well plates in 2 ml of DMEM/10% FCS with IL-2 and/or en-
zyme inhibitors, as specified in Results. Cultures were maintained at 37 C and
5% CO2, and 1 ml of exhausted medium was replaced every 4 d. When used as
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ELISA. Mouse TIL (105 cells) from 3-wk cultures were coincubated for
24 h with an equal number of target cells. The supernatant was then harvested
and tested for released IFN-  in a sandwich ELISA assay (Endogen), follow-
ing the manufacture’s instructions. Data were derived from triplicate wells.
Immunohistochemistry. 4- m tissue sections were cut from formalin-
fixed, paraffin-embedded tissue blocks. After deparaffination, antigen re-
trieval was performed by microwave heating according to the manufac-
turer’s instructions. For TIA-1 staining, tissue sections were heated in 10
mM buffered citrate, pH 6.0 (UCS Diagnostics), 750 W for 15 min. Slides
were cooled at room temperature for 30 min. Sections were incubated
with the primary antibodies (anti-CD4, clone 1F6, 1:40 dilution, Novo
Castra; anti-CD8, clone C/144B, dilution 1:50, DakoCytomation; anti-
iNOS1, dilution 1:50, Lab Vision Corporation; anti-ARG2, clone H-64,
dilution 1:200, Santa Cruz Biotechnology; Inc.; anti-TIA1, clone 2G9,
dilution 1:100, Immunotech; antinitrotyrosine, dilution 1:200, Upstate
Biotechnology) at 37 C for 1 h. Binding antibodies were detected using
biotinylated secondary antibody and avidin-conjugated horseradish perox-
idase (Ultra-tek HRP antipolyvalent SCY, TECK Laboratories). Peroxi-
dase activity was visualized with diaminobenzidine as a chromogen.
Counterstaining with light hematoxylin for 1 min was performed to visu-
alize nuclei. Substitution of the primary antibody with PBS served as neg-
ative control.
TUNEL assay. DNA fragmentation associated with apoptosis was de-
tected in 4- m prostate sections by TUNEL staining, using the ApopTag
kit (S7110-kit, Oncor International) according to the manufacturer’s proto-
col. Sections were counterstained with methyl green 0.1%.
Immunofluorescence. 4- m paraffin sections were cut and mounted on
xilane-coated slides and heated in a microwave 750 W for 20 min in acetate
buffer. Tissue sections were incubated with anti-TIA1 (1:250; Immuno-
tech) for 1 h at room temperature, then washed with PBS and incubated
with a Texas red–conjugated anti–mouse IgG1 (1:1,000; Calbiochem).
After washing in PBS, slides were mounted in 2.5% 1,4-diazobicy-
clo[2.2.2]octane (DABCO, Fluka), 90% glycerol, 10% PBS and were exam-
ined using a confocal microscope (Bio-Rad Laboratories) with 60-magnifi-
cation objective lenses (Nikon). In the case of double staining, after PBS
washing sections were stained for DNA fragmentation, according to manu-
facturer’s guidelines (Oncogene Research Products Fluorescein-FragEL
DNA Fragmentation detection kit). The negative control was generated
substituting PBS for anti-TIA-1 and TdT enzyme. Confocal microscope
was performed with a PerkinElmer Ultra View. Images were analyzed using
the Photoshop 7.0 program (Adobe Systems, Inc.)
Statistical analysis. Results are expressed as mean   SE. Statistical analy-
sis was performed using Student’s t test (Microsoft Office software; Mi-
crosoft Corporation). P   0.05 was considered statistically significant.
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